The rapidly spreading Omicron variant is highly resistant to vaccines, convalescent sera,
and neutralizing antibodies (nAbs), highlighting the urgent need for potent therapeutic nAbs …

The rapid evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Omicron variants has emphasized the need to identify antibodies with broad neutralizing …

The newly emerged Omicron (B. 1.1. 529) variant of SARS-CoV-2 is quickly overtaking the
Delta variant and becoming the dominant strain around the world due to its enhanced …

Therapeutic antibodies are an important tool in the arsenal against coronavirus infection.
However, most antibodies developed early in the pandemic have lost most or all efficacy …

Abstract The SARS-CoV-2 Omicron variant shows substantial resistance to neutralization by
infection-and vaccination-induced antibodies, highlighting the demands for research on the …

The development of neutralizing antibodies (nAbs) is an important strategy to tackle the
Omicron variant. Omicron N-terminal domain (NTD) mutations including A67V, G142D, and …

The emergence and global spread of the SARS-CoV-2 Omicron variants, which carry an
unprecedented number of mutations, raise serious concerns due to the reduced efficacy of …

Background The COVID-19 pandemic continues to pose a significant worldwide threat to
human health, as emerging SARS-CoV-2 Omicron variants exhibit resistance to therapeutic …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern
(VOCs), especially the latest Omicron, have exhibited severe antibody evasion. Broadly …

Antibody therapeutics for the treatment of COVID-19 have been highly successful. However,
the recent emergence of the Omicron variant has posed a challenge, as it evades detection …